Renal complication of crizotinib: Crizotinib-associated complex renal cyst
Keywords:Crizotinib, Non-small cell lung cancer, Complex renal cyst, ALK inhibitor.
Crizotinib is one of the first generations of tyrosine kinase inhibitors targeting anaplastic lymphoma kinase(ALK) and is recently found to be associated with the development of complex renal cysts with inconclusive explanation up to this time. Hereby, we discuss the hypothesis of Crizotinib-associated complex renal cyst development and coexisting renal impairment after initiation of the treatment in a 75-year-old man with ALK-positive non-small cell lung cancer whose complex renal cysts evolved after initiation and cessation of Crizotinib treatment. The coexistence as renal impairment persisted even after switching from Crizotinib to Ceritinib.
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011; 32:605-44.
Binder D, Hegenbarth K. Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol 2013;7:221-34.
Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, et al. Nonsmall cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:548-82.
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat 2018;50:691-700.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-94.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
Yasuma T, Kobayashi T, D'Alessandro-Gabazza CN, Fujimoto H, Ito K, Nishii Y, et al. Renal Injury during Long-Term Crizotinib Therapy. Int J Mol Sci 2018;19:pii:E2902. https://doi.org/10.3390/ijms19102902.
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13: 1011–9.
Di Girolamo M, Paris I, Carbonetti F, Onesti EC, Socciarelli F, Marchetti P. Widespread renal polycystosis induced by crizotinib. Tumori 2015;101:e128– 31. https://doi.org/10.5301/tj.5000338.
Heigener DF, Reck M. Crizotinib. In: Martins UM, editor. Small molecules in oncology. Berlin: Springer; 2014. p. 197–205.
Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-smallcell lung cancer. J Thorac Oncol 2014;9:1720–5.
Schnell P, Bartlett CH, Solomon BJ, Tassell V, Shaw AT, de Pas T, et al. Complex renal cysts associated with crizotinib treatment. Cancer Med 2015;4:887–96.
Souteyrand P, Burtey S, Barlesi F. Multicystic kidney disease: a complication of crizotinib. Diagn Interv Imaging 2015;96:393-5.
XALKORI U.S. Physician prescribing information [Internet]. New York, Revised 2016 March. [Cited 2019 Jan 15]. Available from: http://labeling pfzercom/ShowLabeling.aspx.
Cameron LB, Jiang DH, Moodie K, Mitchell C, Solomon B, Parameswaran BK. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging 2017;17:7.
Baert L, Steg A. On the pathogenesis of simple renal cysts in the adult. A microdissection study. Urol Res 1977;5:103-8.
Tada S, Yamagishi J, Kobayashi H, Hata Y, Kobari T. The incidence of simple renal cyst by computed tomography. Clin Radiol 1983;34:437–9.
Klempner SJ, Aubin G, Dash A, Ou S-HI. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist 2014;19:1008–10.
Bosniak MA. The current radiological approach to renal cysts. Radiology 1986;158:1–10.
Jia JB, Lall C, Tirkes T, Gulati R, Lamba R, Goodwin SC. Chemotherapyrelated complications in the kidneys and collecting system: an imaging perspective. Insights Imaging 2015;6:479–87.
Liaw CW, Palese M, Fabrizio LD. A complex renal cyst in a patient on crizotinib: case report. Urology 2019;131:21-3.
Okubo K, Sato A, Nakamoto K, Hatanaka Y, Isono M, Hatanaka M, et al. Bosniak category III renal cysts caused by crizotinib in an anaplastic lymphoma kinase gene-rearranged non-small cell lung cancer patient. Urology 2018;121:e3–4. https://doi.org/10.1016/j.urology.2018.08.008.
Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep 2016;2:108–23.
Chan WY, Ang MK, Tan DS, Koh WL, Kwek JW. Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report. Radiol Case Rep 2016;11:245–7.
Yoneshima Y, Okamoto I, Arimura-Omori M, Kimura S, Hidaka-Fujimoto N, Iwama E, et al. Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement. Invest New Drugs 2015;33:510–2.
Kim DW, Ahn MJ, Shi Y, De Pas TM, Yang PC, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts [abstract]. J Clin Oncol 2012; 30(15 Suppl):7533.
Eiamprapaporn P, Mungwatthana N, Twinprai P, Sookprasert A, Chindaprasirt J, Ahooja A, et al. Crizotinib-associated renal cysts in anaplastic lymphoma kinase-positive lung cancer patients: A single-center experience. Urol Int 2019; Sep 3:1- 4. https://doi.org/10.1159/000502664.
Taima K, Tanaka H, Tanaka Y, Itoga M, Takanashi S, Tasaka S. Regression of crizotinib-associated complex cystic lesions after switching to alectinib. Intern Med 2017;56:2321-4.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314-22.
Horie S, Kano M, Kawabe K, Mikami Y, Okubo A, Nutahara K, et al. Mediation of renal cyst formation by hepatocyte growth factor. Lancet 1994;344:789-91.
Jayapalan S, Saboorian MH, Edmunds JW, Aukema HM. High dietary fat intake increases renal cyst disease progression in Han: SPRD-cy rats. J Nutr 2000;130:2356–60.
Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH 2nd. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 1997;29:265-72.
Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, et al. Rapid?onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012; 118:5302-9.
Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M, et al. Drug?induced reduction in estimated glomerular filtration rate in patients with ALK?positive non?small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014;120:664–74.
Jhaveri KD, Sakhiya V, Wanchoo R, Ross D, Fishbane S. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int 2016;90:706-7.
Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013;8:e23–4. https://doi.org/10.1097/JTO.0b013e31827e2451.
Jalil AA, Craig J, Bajaj R, Spurling T. Severe ulcerative esophagitis induced by crizotinib therapy. ACG Case Rep J 2014;1:82-4.
Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, et al. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-incidence, radiological features and clinical characteristics. Lung Cancer 2017;106:33–6
How to Cite
Copyright (c) 2020 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)